# Extract Relevant Product Market Definitions From Precedent Decisions > Closes gaps in applying extracted precedent market definitions to the current transaction's specific products, identifying inconsistencies across precedents, and assessing concentration implications under each plausible definition. - Skill: `finchipaiorg/extract-relevant-product-market-definitions-from-precedent-d` (Agent Skill) - Install (CLI): `npx skillmds@latest add finchipaiorg/extract-relevant-product-market-definitions-from-precedent-d` - Raw SKILL.md: https://api.skillmd.com/api/skills/finchipaiorg/extract-relevant-product-market-definitions-from-precedent-d/raw - Safety review: pending - Works with: Claude Code, Claude.ai, OpenAI Codex - Category: Coding & Dev Tools - Author: FinchipAIOrg (https://skillmd.com/u/finchipaiorg) - Updated: 2026-09-22 - Page: https://skillmd.com/skills/finchipaiorg/extract-relevant-product-market-definitions-from-precedent-d --- # Skill: Precedent Market Definition Application ## 1. Subject-matter triage (only if applicable) - This task is an extraction-plus-application exercise: identify the market definitions used in each precedent, then map those definitions onto the overlapping products in the current pharma acquisition review. - Treat each precedent as a distinct analytical unit before synthesizing across them. - If the source set contains multiple candidate product spaces, enumerate them first and analyze each separately rather than collapsing them into a single blended market. ## 2. Failure modes the skill is correcting - Baseline extracts definitions from precedents but does not test whether the current transaction’s products fall within or outside each precedent-defined market; extraction is incomplete unless it is applied to the facts at hand. - Baseline misses conflicts among precedents that define similar product spaces differently; those conflicts must be surfaced because they create both argument openings and litigation vulnerabilities. - Baseline often stops at naming a market and omits the legal test or evidentiary basis used to define it. - Baseline may ignore the downstream consequences of each definition for concentration, competitive overlap, and potential-competition theories. - Baseline may treat biosimilar treatment as uniform across decisions, when the inclusion/exclusion question is context-dependent and must be tied to substitutability and clinical interchangeability. - Baseline may overgeneralize geographic scope; confirm whether each precedent uses a national market and flag any deviation. - Baseline may describe a concern without tying it to the source record and the practical effect on the merger analysis. ## 3. Legal frameworks / domain conventions that apply - Market definition precedent: agencies and courts use prior decisions as benchmarks, but they are not bound by them; the same product space may be defined differently across records depending on the evidence and theory of competition. - Hypothetical monopolist test: the core market-definition tool; ask whether a hypothetical monopolist could profitably impose a small but significant non-transitory increase in price over the candidate market. - Pharmaceuticals often support narrower markets based on mechanism of action, therapeutic class, dosage form, route of administration, formulation, indication, or physician prescribing behavior. - Biosimilar treatment is fact-specific: some precedents include biosimilars with the reference product, while others exclude them based on clinical interchangeability, substitution rules, launch timing, and actual competitive constraints. - Potential competition doctrine matters for pipeline assets: assess whether the pipeline product is likely to enter, when it would commercialize, and whether it would constrain the incumbent product’s pricing or strategy. - Geographic scope in pharma is commonly national in US and EU proceedings; verify the scope used in each precedent before analogizing. - Concentration analysis should be framed under the market definition chosen, with attention to whether one definition produces materially more or less concerning structural outcomes. - Legal propositions should be tied to controlling authority where one is identified in the sources; otherwise use the generally recognized antitrust framework that supports the proposition. ## 4. Analytical scaffolds 1. Build a precedent-by-precedent matrix: - case/decision name as used in the source set - product market defined - analytical method used - included products - excluded products - treatment of biosimilars or pipeline products, if any - geographic scope - evidentiary basis or commercial realities relied upon 2. Compare precedents for internal inconsistency: - identify where the same therapeutic space is treated differently - explain whether the difference is due to factual distinctions, evidence quality, or a true doctrinal split - state the strategic use of the inconsistency for the current transaction 3. Apply each plausible precedent-defined market to the current overlapping products: - for each current product, state whether it fits inside, outside, or arguably within each precedent market - explain the inclusion/exclusion logic by reference to product characteristics, indication, substitutability, and prescribing or dispensing behavior - do not assume that every overlapping product belongs in the same market 4. Address biosimilars separately: - identify decisions that include biosimilars and those that exclude them - test whether the current therapeutic context supports inclusion or exclusion based on clinical interchangeability, access barriers, and substitution dynamics - if the record is mixed, present both sides and identify which is stronger on the existing facts 5. Analyze pipeline overlap under the potential-competition framework: - for each pipeline product targeting the same indication, identify the stage of development, probability of approval, expected timing to market, and likely competitive constraint - evaluate whether the pipeline asset is close enough to discipline current pricing or strategic conduct under the applicable precedent - distinguish actual overlap from speculative future overlap 6. Run concentration implications under each plausible definition: - compare the structural picture across alternative markets - identify which definition is most favorable and which is least favorable to the client - if source materials provide share or size data, use those figures in the analysis; if they do not, state that the concentration impact cannot yet be quantified from the record and explain what additional data would be needed - where a threshold or benchmark is used in the source set, cite and apply that benchmark rather than inventing one 7. Confirm geographic scope: - verify whether each precedent is national or otherwise - if a decision departs from the expected national frame, flag the exception and explain whether it is likely transferable to the current review 8. Close each issue analytically: - tie the point to the source record - state the legal or strategic consequence for the merger analysis - identify the practical implication for the client’s preferred market framing ## 5. Vertical / structural / temporal relationships (only if applicable) - Vertical relationship: distinguish upstream input markets from downstream finished-product markets when the precedent does so, and do not merge them absent support. - Horizontal relationship: assess whether the current products compete at the same level of the supply chain and whether the precedent treats them as direct substitutes. - Temporal relationship: distinguish present commercial products from pipeline products that may enter later; do not treat expected future entry as present market participation unless the precedent and record support it. - If the source set contains more than one time period or development stage, analyze each one separately before drawing a consolidated view. ## 6. Output structure conventions - Use an internal working matrix first, then write the memo from that matrix. - Organize the memo in conventional antitrust form rather than copying any rubric-specific section list. - A practical structure is: - short introduction and scope - precedent matrix - synthesis of conflicts and common themes - application to the current overlapping products - concentration / structural implications under alternative definitions - recommended market-definition position and vulnerabilities - When stating a legal proposition, name the governing antitrust framework or authority that supports it. - When discussing multiple precedents, preserve one row or subsection per decision rather than blending them. - When the record does not permit a conclusion, say so expressly and identify the missing factual predicate. - End with a concise Recommended Actions section that gives the next analytical or evidentiary steps, the responsible role, and the timing relative to the merger review milestone.